NO20062319L - Kontrollerte frigivelsessterile injiserbare aripiprazolpreparater og fremgangsmate - Google Patents

Kontrollerte frigivelsessterile injiserbare aripiprazolpreparater og fremgangsmate

Info

Publication number
NO20062319L
NO20062319L NO20062319A NO20062319A NO20062319L NO 20062319 L NO20062319 L NO 20062319L NO 20062319 A NO20062319 A NO 20062319A NO 20062319 A NO20062319 A NO 20062319A NO 20062319 L NO20062319 L NO 20062319L
Authority
NO
Norway
Prior art keywords
aripiprazole
sterile injectable
preparations
methods
controlled release
Prior art date
Application number
NO20062319A
Other languages
English (en)
Other versions
NO334919B1 (no
Inventor
Janusz W Kostanski
Takakuni Matsuda
Manjo Nerurkar
Vijay H Naringrekar
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34549292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062319(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NO20062319L publication Critical patent/NO20062319L/no
Publication of NO334919B1 publication Critical patent/NO334919B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det tilveiebringes steril, injiserbar aripiprazolformulering med kontrollert frigivelse, som er dannet av aripiprazol av en ønsket, gjennomsnittlig partikkelstørrelse og et vehikkel for dette, som ved kondisjonering med vann og intramuskulær injeksjon frigir aripiprazol i en periode på minst omtrent én uke og opp til omtrent åtte uker. Det frembringes også en fremgangsmåte for fremstilling av den frysetørkede aripiprazol-formuleringen med kontrollert frigivelse, og en fremgangsmåte for behandling av schizofreni ved å anvende formuleringen.
NO20062319A 2003-10-23 2006-05-22 Sterilt, injiserbart aripiprazolpreparat med kontrollert frigjøring, et injiserbart preparat som inneholder det sterile, frysetørrede aripiprazol, en fremgangsmåte for fremstilling av preparatet, og anvendelse av preparatet til å fremstilling av et medikament for behandling av schizofreni. NO334919B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51361803P 2003-10-23 2003-10-23
PCT/US2004/034367 WO2005041937A2 (en) 2003-10-23 2004-10-18 Controlled release sterile injectable aripiprazole formulation and method

Publications (2)

Publication Number Publication Date
NO20062319L true NO20062319L (no) 2006-07-21
NO334919B1 NO334919B1 (no) 2014-07-14

Family

ID=34549292

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20062319A NO334919B1 (no) 2003-10-23 2006-05-22 Sterilt, injiserbart aripiprazolpreparat med kontrollert frigjøring, et injiserbart preparat som inneholder det sterile, frysetørrede aripiprazol, en fremgangsmåte for fremstilling av preparatet, og anvendelse av preparatet til å fremstilling av et medikament for behandling av schizofreni.
NO2014027C NO2014027I1 (no) 2003-10-23 2014-10-27 Aripiprazol (preparat - krav 1 og 2 i patentet)

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2014027C NO2014027I1 (no) 2003-10-23 2014-10-27 Aripiprazol (preparat - krav 1 og 2 i patentet)

Country Status (33)

Country Link
US (11) US7807680B2 (no)
EP (1) EP1675573B2 (no)
JP (2) JP4836797B2 (no)
KR (1) KR100931784B1 (no)
CN (1) CN1870980B (no)
AR (2) AR046141A1 (no)
AT (1) ATE411797T2 (no)
AU (1) AU2004285448C1 (no)
BR (1) BRPI0415531B8 (no)
CA (1) CA2543242C (no)
CO (1) CO5690539A2 (no)
CY (2) CY1109040T1 (no)
DE (1) DE602004017342D1 (no)
DK (1) DK1675573T4 (no)
EC (2) ECSP066512A (no)
ES (1) ES2315721T5 (no)
FR (1) FR14C0039I1 (no)
GE (1) GEP20115205B (no)
HK (1) HK1095266A1 (no)
IL (1) IL175072A (no)
LU (1) LU92427I2 (no)
MX (1) MXPA06004489A (no)
MY (1) MY146093A (no)
NO (2) NO334919B1 (no)
NZ (1) NZ546063A (no)
PE (1) PE20050811A1 (no)
PL (1) PL1675573T4 (no)
PT (1) PT1675573E (no)
SI (1) SI1675573T2 (no)
TW (2) TWI383810B (no)
UA (1) UA82561C2 (no)
WO (1) WO2005041937A2 (no)
ZA (1) ZA200602347B (no)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
EP1812397A1 (en) * 2004-11-18 2007-08-01 Synthon B.V. Process of making crystalline aripiprazole
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8865722B2 (en) 2006-01-05 2014-10-21 Teva Pharmaceutical Industries Ltd. Wet formulations of aripiprazole
CA2627695A1 (en) * 2006-01-05 2007-07-19 Teva Pharmaceutical Industries Ltd. Dry formulations of aripiprazole
TR200604349A2 (tr) * 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
US10632079B2 (en) * 2007-06-25 2020-04-28 Otsuka Pharmaceuticals Co., Ltd. Microspheres having core/shell structure
MY152789A (en) * 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
CA2763456C (en) 2009-05-27 2017-10-24 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
KR101125210B1 (ko) * 2009-09-11 2012-03-19 주식회사 대웅제약 아리피프라졸-벤토나이트-ａｅａ 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
CN102218040A (zh) * 2010-04-13 2011-10-19 齐鲁制药有限公司 一种阿立哌唑组合物微晶的口腔崩解片及其制备方法
IL206739A (en) * 2010-06-30 2016-06-30 David Segal An injectable drug containing silitol as an active substance
AR082494A1 (es) * 2010-08-24 2012-12-12 Otsuka Pharma Co Ltd Composicion en torta y en suspension con contenido de derivado de carbostirilo y derivado de aceite de silicona y/o aceite de silicona
CA2814840C (en) 2010-10-18 2018-08-28 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
AU2011320758B2 (en) * 2010-10-28 2015-09-24 Alpha To Omega Pharmaceutical Consultants, Inc. Aripiprazole compositions and methods for its transdermal delivery
US9757374B2 (en) * 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
AR083884A1 (es) 2010-11-16 2013-03-27 Otsuka Pharma Co Ltd Jeringa prellenable de doble camara y relleno de aripiprazol en la jeringa
CN102525915B (zh) * 2010-12-14 2016-09-28 江苏豪森药业集团有限公司 一种持续释放的注射制剂及其制备方法和用途
KR101905215B1 (ko) * 2011-01-24 2018-10-05 오츠카 세이야쿠 가부시키가이샤 아리피프라졸을 유효 성분으로 포함하는 케이크 형상 조성물이 함유된 의료용 기구 및 아리피프라졸을 유효 성분으로 포함하는 케이크 형상 조성물
HRP20240285T1 (hr) 2011-03-18 2024-05-24 Alkermes Pharma Ireland Limited Farmaceutski pripravci koji sadrže sorbitan estere
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102850268B (zh) * 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
GB2505860B (en) * 2011-06-27 2018-10-31 Shanghai Zhongxi Pharmaceutical Corp Aripiprazole medicament formulation and preparation method therefor
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
ES2691092T3 (es) 2012-08-21 2018-11-23 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
AU2013305907B2 (en) 2012-08-21 2018-01-18 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
PL2888286T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
CN108640996A (zh) 2012-08-21 2018-10-12 詹森药业有限公司 帕潘立酮的抗体及其用途
JP2015529199A (ja) 2012-08-21 2015-10-05 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンハプテンに対する抗体及びその使用
WO2014080285A2 (en) 2012-09-19 2014-05-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
KR101759017B1 (ko) * 2013-04-30 2017-07-17 오쓰까 세이야꾸 가부시키가이샤 아리피프라졸을 포함하는 경구 고형 제제 및 아리피프라졸을 포함하는 경구 고형 제제의 제조방법
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
BR112016021535A8 (pt) * 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
CN106794251B (zh) * 2014-08-18 2020-12-29 阿尔科姆斯制药爱尔兰有限公司 阿立哌唑前体药物组合物
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
DK3185867T3 (da) * 2014-08-25 2021-03-15 Alkermes Pharma Ireland Ltd Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
TWI584823B (zh) * 2015-08-31 2017-06-01 諾瑞特國際藥業股份有限公司 具有延長的保存期限的阿立哌唑可注射懸浮液製劑
CN106474058B (zh) * 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
JP6504019B2 (ja) * 2015-10-27 2019-04-24 豊田合成株式会社 発光装置
EP3390449A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica N.V. Antibodies to risperidone and use thereof
MA44067A (fr) 2015-12-17 2018-10-24 Janssen Pharmaceutica Nv Anticorps dirigés contre la quétiapine et utilisation associée
CN105663057A (zh) * 2015-12-30 2016-06-15 中国药科大学 阿立哌唑长效混悬剂及其制备方法
EP3490529A1 (en) * 2016-07-28 2019-06-05 Mylan Laboratories Ltd. Process for preparing sterile aripiprazole formulation
AU2019230014A1 (en) 2018-03-05 2020-09-17 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) * 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
KR102486564B1 (ko) * 2019-08-23 2023-01-19 주식회사 대웅테라퓨틱스 니클로사마이드 지연방출 조성물 및 이의 항바이러스 용도
US20230310417A1 (en) 2020-03-30 2023-10-05 Cipla Limited Injectable aripiprazole formulation
CA3163321C (en) * 2020-04-01 2023-12-19 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
KR102606504B1 (ko) * 2020-04-10 2023-11-29 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
WO2021233402A1 (zh) * 2020-05-21 2021-11-25 江苏先声药业有限公司 一种含依匹哌唑药物组合物及其制备方法
CN112656761B (zh) * 2020-12-30 2023-09-08 河南合智医药科技有限公司 一种低刺激性阿立哌唑前药的油溶缓释注射制剂及其制备方法
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115554253B (zh) * 2022-10-14 2024-03-29 浙江圣兆药物科技股份有限公司 一种平稳释药的注射用阿立哌唑冻干制剂及其制备方法
GR1010656B (el) * 2023-03-23 2024-03-21 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει εναν ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
GR1010624B (el) * 2023-03-23 2024-01-30 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει αριπιπραζολη και μεθοδος για την παρασκευη αυτου

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB209551A (en) 1922-11-20 1924-01-17 William Mortimer Melmore Improvements in or relating to petrol and other cans
US4038389A (en) 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
CA1209477A (en) 1981-03-26 1986-08-12 Bruce E. Haeger Composition of matter comprising a lyophilized preparation of a penicillin derivative
JPS5832899A (ja) 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
US4352811A (en) 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
IL68549A (en) * 1983-05-03 1988-05-31 Kit Medidont Ltd Method and instrument for measuring moisture
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JPH03212852A (ja) 1990-01-18 1991-09-18 Hitachi Electron Eng Co Ltd 記録媒体カートリッジ搬送装置における送り機構
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
IT1244880B (it) 1990-12-11 1994-09-12 Torre A Farmaceutici Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
KR100354270B1 (ko) * 1993-11-19 2003-02-11 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii 마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸
WO1995033488A1 (en) 1994-06-02 1995-12-14 Quadrant Holdings Cambridge Limited Method of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
RU2082401C1 (ru) 1994-08-18 1997-06-27 Фармацевтическое акционерное общество "Ферейн" Способ получения лекарственной формы комбинированного препарата
US6165442A (en) 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
WO1998008489A1 (en) 1996-08-26 1998-03-05 Transgene S.A. Cationic lipid-nucleic acid complexes
US6297231B1 (en) * 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
DE69935433T2 (de) 1998-07-30 2007-10-25 Point Biomedical Corp., San Carlos Neuer wirkstoffträger für die gefriertrocknung von wässrigen suspensionen von mikropartikeln
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
CN1227235C (zh) 1999-12-09 2005-11-16 辛根塔参与股份公司 作为杀菌剂的吡唑羧酰胺和吡唑硫代羧酰胺
JP2001187735A (ja) * 2000-01-05 2001-07-10 Towa Yakuhin Kk 安定なニコランジル含有粉末の製造法
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
RU2169574C1 (ru) 2000-01-27 2001-06-27 Кобатов Алексей Иванович Способ получения биопрепарата и сухой биопрепарат
AU2001233180A1 (en) 2000-02-10 2001-08-20 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
WO2001072699A1 (en) 2000-03-27 2001-10-04 The Scripps Research Institute Inhibition of angiogenesis and tumor growth
US20030026844A1 (en) 2000-04-18 2003-02-06 Hee-Yong Lee Injectable sustained release pharmaceutical composition and processes for preparing the same
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002241284A (ja) * 2001-02-16 2002-08-28 Towa Yakuhin Kk 全身投与用アルガトロバン注射液
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
CN1813699B (zh) 2001-06-14 2012-04-18 大塚制药株式会社 药物组合物
DE60224293T2 (de) 2001-09-21 2008-12-11 Egalet A/S Feste dispersionen mit kontrollierter freisetzung von carvedilol
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
PE20030445A1 (es) * 2001-09-25 2003-07-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ITMI20020808A1 (it) 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
AU2003261167A1 (en) * 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
RU2342931C2 (ru) * 2002-08-20 2009-01-10 Бристол-Маерс Сквибб Компани Состав на основе комплекса арипипразола
WO2004064752A2 (en) * 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
ATE411797T2 (de) * 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
CA2543296A1 (en) 2003-10-31 2005-05-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents

Also Published As

Publication number Publication date
SI1675573T2 (sl) 2012-08-31
IL175072A0 (en) 2006-08-20
ES2315721T5 (es) 2012-08-24
WO2005041937A2 (en) 2005-05-12
US20140018369A1 (en) 2014-01-16
AU2004285448C1 (en) 2021-08-19
SI1675573T1 (sl) 2009-02-28
US20080112985A1 (en) 2008-05-15
US20120100190A1 (en) 2012-04-26
WO2005041937A3 (en) 2006-04-06
LU92427I9 (no) 2019-01-17
KR20060118450A (ko) 2006-11-23
NZ546063A (en) 2009-05-31
CY2014021I1 (el) 2014-07-02
US8722679B2 (en) 2014-05-13
US20080112986A1 (en) 2008-05-15
US20200061057A1 (en) 2020-02-27
IL175072A (en) 2015-06-30
TWI383810B (zh) 2013-02-01
AR046141A1 (es) 2005-11-23
US7807680B2 (en) 2010-10-05
US20150024056A1 (en) 2015-01-22
RU2342927C2 (ru) 2009-01-10
US20210338663A1 (en) 2021-11-04
HK1095266A1 (en) 2007-05-04
EP1675573B2 (en) 2012-06-13
JP2011102316A (ja) 2011-05-26
ECSP066512A (es) 2006-10-10
NO2014027I1 (no) 2014-11-10
US8952013B2 (en) 2015-02-10
JP4836797B2 (ja) 2011-12-14
UA82561C2 (uk) 2008-04-25
ECSP12006512A (es) 2012-02-29
US20080221121A1 (en) 2008-09-11
FR14C0039I1 (fr) 2014-06-27
CA2543242A1 (en) 2005-05-12
PL1675573T4 (pl) 2016-04-29
AR106449A2 (es) 2018-01-17
CN1870980B (zh) 2010-06-23
AU2004285448B2 (en) 2009-06-11
JP2007509148A (ja) 2007-04-12
ATE411797T2 (de) 2008-11-15
CN1870980A (zh) 2006-11-29
US9763935B2 (en) 2017-09-19
ES2315721T9 (es) 2015-11-05
ES2315721T3 (es) 2009-04-01
EP1675573B1 (en) 2008-10-22
PL1675573T5 (pl) 2012-10-31
US20170348308A1 (en) 2017-12-07
CY1109040T1 (el) 2014-07-02
BRPI0415531B8 (pt) 2021-05-25
CA2543242C (en) 2015-04-14
AU2004285448A1 (en) 2005-05-12
NO334919B1 (no) 2014-07-14
DK1675573T3 (da) 2009-01-05
BRPI0415531B1 (pt) 2019-07-30
GEP20115205B (en) 2011-04-26
TW201204413A (en) 2012-02-01
DE602004017342D1 (de) 2008-12-04
US8030313B2 (en) 2011-10-04
NO2014027I2 (no) 2014-10-27
BRPI0415531A (pt) 2006-12-26
TW200524638A (en) 2005-08-01
MY146093A (en) 2012-06-29
MXPA06004489A (es) 2006-06-20
US20080107745A1 (en) 2008-05-08
US20050148597A1 (en) 2005-07-07
CO5690539A2 (es) 2006-10-31
RU2006109111A (ru) 2007-09-27
ZA200602347B (en) 2007-09-26
EP1675573A2 (en) 2006-07-05
JP5372032B2 (ja) 2013-12-18
PL1675573T3 (pl) 2009-04-30
KR100931784B1 (ko) 2009-12-14
PT1675573E (pt) 2008-12-30
PE20050811A1 (es) 2005-09-25
DK1675573T4 (da) 2012-08-06
TWI421101B (zh) 2014-01-01
LU92427I2 (fr) 2014-06-11
CY2014021I2 (el) 2017-03-15

Similar Documents

Publication Publication Date Title
NO20062319L (no) Kontrollerte frigivelsessterile injiserbare aripiprazolpreparater og fremgangsmate
DE60207685D1 (de) Verfahren zur herstellung von l-threonin
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
DE60138804D1 (de) Verfahren zur herstellung von physiologisch aktiven substanzen enthaltenden dispersionen unter anwendung von hochdruck und hochscherkraft
ATE495177T1 (de) Verfahren zur behandlung von arzneimittelinduzierter peripherer neuropathie und verwandten krankheitsformen
DE60325463D1 (de) Verfahren zur herstellung eines biozids, das stabilisiertes hypochlorid und eine bromidionenquelle enthält, sowie verfahren zur bekämpfung von mikroorganismen-fouling, bei dem dieses biozid verwendet wird
WO2006130607A3 (en) Controlled-release formulation useful for treating disorders associated with hepatitis c virus
MX2007006610A (es) Metodo para simplificar acidos nucleicos microbianos por modificacion quimica de citosinas.
MY145131A (en) Method and composition for high level disinfection employing quaternary ammonium compounds
TW200510317A (en) Caspase inhibitors and uses thereof
WO2008127296A3 (en) Methods and compositions for treating tularemia
DE602006019754D1 (de) Verfahren und zusammensetzung, die immunomodulatorische verbindungen zur behandlung von mit niedrigen plasmaleptin-spiegeln in zusammenhang stehenden störungen verwenden
AU2003298972A1 (en) Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
TW200502234A (en) Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
WO2006027691A3 (en) Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds
AR035251A1 (es) Proceso para la preparacion del fungicida agricola azoxistrobin y analogos del mismo, intermediarios quimicos para obtener el mismo y procesos para preparar intermediarios
WO2004043365A3 (en) Method for treatment of premature ejaculation in humans
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
WO2003059262A3 (en) Method and composition for treating and preventing hiv infection and aids
WO2003064385A3 (de) Delta1-pyrroline und deren verwendung als schädlingsbekämpfungsmittel
NO20002525L (no) Blanding anvendelig som overflateaktiv emulgator og dispersjon, fremgangsmÕte for fremstilling derav samt anvendelse av den
MXPA04004075A (es) Compuesto y metodo para tratamiento de vejiga hiperactiva.
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
DE69821925D1 (de) Verfahren zur herstellung eines aminoalkohol

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: ABILIFY MAINTENA - ARIPIPRAZOL; REG. NO/DATE: EU/1/13/882-001-004 20131216

Spc suppl protection certif: 2014027

Filing date: 20141027

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: ABILIFY MAINTENA - ARIPIPRAZOL; REG. NO/DATE: EU/1/13/882-001-004 20131216; FIRST REG. NO/DATE: EU/1/13/882-001-004 20131119

Spc suppl protection certif: 2014027

Filing date: 20141027

Extension date: 20281119